Latest News and Press Releases

BASEL, Switzerland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the 2021 Baird Global...

BASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and men, today announced the appointment of Uneek Mehra...

First fiscal quarter 2021 total revenues of $41.1 million; net product revenue from U.S. sales of ORGOVYX® of $10.5 million and MYFEMBREE® of $1.1 millionMYFEMBREE approved by the U.S. FDA in May 2021...

RYEQO is the first and only once-daily long-term treatment for uterine fibroids in EuropeIndication has no limitation for duration of use, as supported by safety and efficacy data from the Phase 3...

BASEL, Switzerland, July 14, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and...

BASEL, Switzerland, June 01, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public...

In the Phase 3 LIBERTY 1 and LIBERTY 2 studies, MYFEMBREE demonstrated 72.1% and 71.2% response rates in menstrual blood loss (MBL) at Week 24, with MBL reductions of 82.0% and 84.3% from...

CHMP opinion recommending approval based on data from the Phase 3 LIBERTY program in women with uterine fibroidsGedeon Richter will commercialize RYEQO for uterine fibroids, if approved, in...

Fourth fiscal quarter 2020 total revenues of $24.6 million; net product revenue from sales of ORGOVYX in the U.S. of $3.6 millionFDA review of New Drug Application for relugolix combination tablet for...

BASEL, Switzerland, May 04, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and...